RESUMO
La coinfección con los virus de hepatitis B (VHB) y/o hepatitis C (VHC) puede provocar complicaciones en el paciente VIH+. El objetivo de este estudio fue evaluar la frecuencia de marcadores serológicos en la coinfección del VHB y/o VHC en plasmas de pacientes infectados por VIH y su correlación con el estatus virológico del VIH e inmunológico del paciente. Se evaluaron 1.846 plasmas positivos para VIH, referidos al Instituto Nacional de Higiene Rafael Rangel para la determinación de marcadores serológicos del VHB y VHC. Se realizaron análisis de carga viral del VIH-1 y recuento de linfocitos T CD4+/CD8+ para evaluar el estatus virológico e inmunológico, respectivamente de la población estudiada. La frecuencia de coinfección por VHB ó VHC fue de 15% y 5%, respectivamente mientras que la coinfección VHB/VHC fue de 0,16% (3/1.846) en pacientes infectados por VIH. No se observó asociación entre presencia de marcadores serológicos del VHB ó el VHC y bajos ó elevados niveles de ARN genómico del VIH (p=0,81 y p=0,31, respectivamente) ni valores bajos ó normales del índice CD4/CD8 (p=0,75 y p=0,06, respectivamente). Estos resultados sugieren que la coinfección con VHB o VHC no parece influir en los estatus virológico e inmunológico de la población evaluada.
Co-infection with hepatitis B (HBV) virus and/or hepatitis C (HCV) virus can induce complications in HIV+ patients. The purpose of this study was to evaluate the frequency of serologic markers in HBV and/ or HCV in plasma of HIV infected patients, and its correlation with the HIV viral status and the immunological status of the patient. The study included the evaluation of 1,846 HIV positive plasmas referred to the Instituto Nacional de Higiene Rafael Rangel for the determination of HBV and HCV serologic markers. The evaluation of the viral and immunological status was done by the analysis of the HIV-1 viral load and CD4+/CD8+ T lymphocyte counts, respectively, in the population studied. The frequency of HBV or HCV co-infection was 15% and 5%, respectively, while HBV/HCV co-infection was 0.16% (3/1,846) in HIV infected patients. There was no association between the presence of HBV or HCV serologic markers and low or normal values of the HIV genomic RNA (p=0.81 and p=0.31, respectively) nor low or normal values of the CD4/CD8 index (p=0.75 and p=0.06, respectively). These results suggest that HBV or HCV co-infection does not seem to influence the viral and immunological status of the evaluated population.
RESUMO
This study evaluated total lymphocyte count (TLC) as a substitute marker for CD4+ cell counts to identify patients who need prophylaxis against opportunistic infection (CD4 < 200 cells/mm³) and patients with CD4 < 350 cells/mm³ (Brazilian threshold value of CD4 count to define AIDS). We evaluated TLC and CD4+ cells count of 1,174 HIV-infected patients, in Salvador, Brazil, from May 2003 to September 2004. CD4+ cell counts were performed by flow cytometry, and TLC was measured with an automated hematological counter. The mean CD4 count was 430 cells/mm³ (range: 4 to 2,531 cells/mm³). Mean TLC was 1,900 cells/mm³ (range: 300 to 6,200 cells/mm³). Using a threshold value of 1,000 cells/mm³ for TLC, the positive predictive value (PPV) was 77 percent for CD4 < 200 cells/mm³, but the sensitivity was only 29 percent, while the negative predictive value (NPV) was 88 percent, with 98 percent specificity. Similar findings were observed for CD4 count < 350. Using the same threshold value of 1,000 cells/mm³ for TLC, sensitivity was 14 percent, and specificity 99 percent (PPV= 94 percent; NPV=62 percent). In 70/1,510 (5 percent) of the samples the sum of CD4 and CD8 cell counts was greater than the TLC and in 27 percent (419/1,510) this sum was below 65 percent of the TLC. TLC has a high specificity to identify patients for prophylaxis, but a quite low sensitivity. It is not useful as an alternative to CD4+ T-cell counts as a marker in HIV-infected patients.